Fluvoxamine should not be combined with other SSRIs, MAO inhibitors, or potent serotonergic agents without close medical supervision because of the increased risk of serotonin syndrome. If augmentation is needed, a clinician may prefer adding non-serotonergic agents such as atypical antipsychotics under strict monitoring.
Fluvoxamine is classified as a Category C medication in the UK, meaning animal studies have shown some risk, but there are no well-controlled studies in pregnant women. It should only be used when the expected benefit justifies potential fetal risk, and the decision should involve both obstetric and psychiatric specialists.
Both contain the same active ingredient, Fluvoxamine Maleate, and must meet the same regulatory standards for safety, efficacy, and quality. Differences may lie only in inactive excipients, which rarely affect therapeutic outcome.
Most patients notice an improvement in anxiety or obsessive-compulsive symptoms within 2-4 weeks, but full benefits often emerge after 8-12 weeks of consistent dosing.
Alcohol is not prohibited, but it can increase sedation and impair judgement, especially during dose initiation. Moderation and awareness of personal tolerance are advisable.
Key symptoms include agitation, confusion, rapid heart rate, high blood pressure, dilated pupils, muscle rigidity, tremor, sweating, and fever. If these appear, seek emergency medical care immediately.
Routine blood monitoring is not required for most patients. However, liver function tests may be performed in individuals with pre-existing liver disease or if symptoms suggest hepatic issues.
During the first few weeks, some people experience dizziness or drowsiness. It is prudent to assess personal response before operating vehicles or heavy machinery, especially after dose changes.
If the missed dose is more than six hours away from the next scheduled dose, take it as soon as you remember. Do not take a double dose to compensate for the missed one.
In the UK, Fluvoxamine is not first-line for major depressive disorder; it is primarily indicated for OCD and social anxiety. Clinicians may prescribe it off-label for depression when other options are unsuitable, but this should be a carefully considered decision.
Fluvoxamine is an antidepressant medication that contains Fluvoxamine Maleate as its active component. It belongs to the selective serotonin reuptake inhibitor (SSRI) class and is marketed in the United Kingdom as a prescription-only pill. The medication is available in strengths of 50 mg and 100 mg. Like other SSRIs, Fluvoxamine works by influencing serotonin levels in the brain, helping to improve mood and reduce certain anxiety-related symptoms.
Fluvoxamine inhibits the re-uptake of serotonin (5-hydroxytryptamine) into presynaptic neurons. By blocking the serotonin transporter (SERT), it increases the amount of serotonin available in the synaptic cleft, which enhances neurotransmission in pathways involved in mood regulation and anxiety control.
Fluvoxamine is approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the following indications:
These indications are based on pivotal clinical trials demonstrating efficacy compared with placebo and, in some cases, with other SSRIs.
Major interactions:
MAOIs - risk of serotonin syndrome; must observe a 14-day washout period.
Strong CYP2D6 inhibitors (e.g., quinidine, bupropion) - may increase Fluvoxamine plasma concentrations.
Moderate interactions:
Other serotonergic agents (tricyclic antidepressants, tramadol, St John’s wort) - increase serotonin syndrome risk; dosage adjustments or enhanced monitoring may be needed.
Anticoagulants (warfarin) - Fluvoxamine can modestly increase INR; monitor coagulation parameters.
General advisory: Patients should provide a complete list of all medicines, supplements, and herbal products to their healthcare provider before starting Fluvoxamine.
If a dose is missed and the next scheduled dose is more than 6 hours away, take the missed tablet as soon as remembered. Do not double the dose to catch up.
Symptoms may include rapid heartbeat, dizziness, nausea, and seizures. Seek emergency medical care immediately; supportive measures and monitoring are the mainstays of treatment.
Abrupt cessation can lead to discontinuation syndrome (e.g., flu-like symptoms, electric-shock sensations). A gradual taper, typically reducing the dose by 25 % every 1-2 weeks, is recommended under medical supervision.
This article provides educational information about Fluvoxamine and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
